How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
progress on TSHA-102 for Rett syndrome and receiving FDA Breakthrough Therapy designation. The company's preparation for potential commercialization, including the hiring of veteran market access executive Brad Martin and alignment with the FDA on pivotal trial designs, underscores how seriously it is positioning TSHA-102 for a future launch. Next, we'll examine how the Breakthrough Therapy designation for TSHA-102 may reshape Taysha's investment narrative and future risk profile. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Taysha Gene Therapies Investment Narrative Recap To own Taysha Gene Therapies, you have to believe TSHA-102 for Rett syndrome can move from promising trials to a real commercial product, before cash burn and
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies (TSHA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TSHA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "seMarketBeat
- Taysha Gene Therapies (TSHA) had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (TSHA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
TSHA
Earnings
- 3/19/26 - Miss
TSHA
Sec Filings
- 3/19/26 - Form 10-K
- 3/19/26 - Form 8-K
- 2/27/26 - Form 144
- TSHA's page on the SEC website